不可切除III期非小细胞肺癌同步化质子治疗的长期结局:日本全国登记研究
该研究基于日本粒子线治疗委员会前瞻性登记数据库,分析2016年5月至2020年6月接受同步化质子治疗(CCPT)的不可切除III期非小细胞肺癌(NSCLC)患者。共156例符合标准,中位随访49.0个月,2年和5年总生存率分别为72.9%和43.7%,2年和5年无进展生存率分别为35.4%和21.3%。结论认为CCPT安全有效,即使对不适于光子胸部放疗者也可行根治性治疗。
要点
- CCPT对不可切除III期NSCLC安全有效,5年总生存率达43.7%。
- 2级和3级放射性肺炎发生率分别为19.9%和3.2%,无≥4级晚期毒性。
- 不适于光子根治性放化疗者仍可从CCPT中获益,5年总生存率27.5%。
核心结论
- CCPT对不可切除III期NSCLC被认为是安全有效的。
- 即使不适于光子胸部根治性放化疗的患者,也可通过CCPT实现根治性治疗。
研究设计与样本
- 日本放射肿瘤粒子线治疗委员会前瞻性登记数据库分析。
- 纳入2016年5月至2020年6月组织学确诊的不可切除III期NSCLC接受CCPT者,共170例入组,156例符合标准。
主要发现
- 中位随访49.0个月,2年和5年总生存率分别为72.9%(95%CI 66.2-80.4)和43.7%(95%CI 35.8-53.3)。
- 2年和5年无进展生存率分别为35.4%(95%CI 28.5-43.8)和21.3%(95%CI 15.0-30.1)。
- 2级和3级放射性肺炎发生率分别为19.9%和3.2%,无≥4级晚期毒性。
- 31例不适于光子根治性放化疗者,2年和5年总生存率分别为58.1%(95%CI 43.1-78.3)和27.5%(95%CI 14.2-53.4)。
- 66例(42%)接受免疫检查点抑制剂(ICI)辅助治疗;10例(6.4%)合并间质性肺炎;31例(20%)因超出正常剂量限值不适于光子根治性放化疗。
关键数值与推荐
- 剂量分割统一标准为60-74 Gy(相对生物效应)分30-37次,照射范围至淋巴结区域由主治放射肿瘤医生决定。
- 毒性评价采用常见不良事件术语标准4.0版。
临床怎么用
- CCPT可作为不可切除III期NSCLC的根治性治疗选择,尤其对不适于光子放疗者。
- 治疗中需关注放射性肺炎,但≥4级晚期毒性未见报告。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We aimed to analyze the data from the Japan Association for Radiation Oncology Particle Beam Therapy Committee's prospective registration database to evaluate the clinical efficacy and safety of concurrent chemo-proton therapy (CCPT) for unresectable stage III non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: The data of patients with histologically confirmed unresectable stage III NSCLC who received CCPT between May 2016 and June 2020 were extracted. Dose fractionation within the unified standard of 60-74 Gy relative biological effectiveness over 30-37 fractions and irradiation range to lymph node regions was determined at the discretion of the attending radiation oncologists. Immune checkpoint inhibitor (ICI) as adjuvant therapy was mostly administered after the provision of insurance coverage in August 2018. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. RESULTS: A total of 170 patients were enrolled, of whom 156 met the eligibility criteria, including 10 patients (6.4 %) with interstitial pneumonia and 31 patients (20 %) who were ineligible for definitive chemo-radiation using x-rays due to exceeding normal dose constraints. Sixty-six patients (42 %) received ICI as adjuvant therapy. The median follow-up duration was 49.0 months, 2 and 5-year overall survivals were 72.9 % (95 % confidence interval: 66.2-80.4) and 43.7 % (35.8-53.3), and 2 and 5-year progression-free survivals were 35.4 % (28.5-43.8) and 21.3 % (15.0-30.1), respectively. Grade 2 or 3 radiation pneumonitis was observed in 19.9 % and 3.2 % of the patients, respectively, and there were no grade ≥ 4 late toxicities. In the 31 patients who were not eligible for definitive chemo-radiation using x-rays, the 2 and 5-year overall survivals were 58.1 % (43.1-78.3) and 27.5 % (14.2-53.4), respectively. CONCLUSION: CCPT for unresectable stage III NSCLC is considered safe and effective. Definitive treatment was possible even in patients who were not eligible for photon thoracic radiotherapy.
引用
- Iwata H, Murakami M, Maruo K, et al. Long-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry study. Radiother Oncol. 2025. PMID: 41314394. doi:10.1016/j.radonc.2025.111307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。